Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104)
Chao Zhang(Guangdong Academy of Medical Sciences), Wen‐Zhao Zhong(Guangdong Academy of Medical Sciences)
Cited by 31
Related Papers
Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status
|Journal of Hematology & Oncology|2015|89